Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
EBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsShares IssuedShares OutstandingShares Outstanding
Ratios

Summit Therapeutics (SMMT) Receivables - Net (2017 - 2022)

Summit Therapeutics filings provide 7 years of Receivables - Net readings, the most recent being $349000.0 for Q4 2022.

  • Quarterly Receivables - Net fell 76.16% to $349000.0 in Q4 2022 from the year-ago period, while the trailing twelve-month figure was $349000.0 through Dec 2022, down 76.16% year-over-year, with the annual reading at $349000.0 for FY2022, 76.16% down from the prior year.
  • Receivables - Net hit $349000.0 in Q4 2022 for Summit Therapeutics, up from $140000.0 in the prior quarter.
  • Across five years, Receivables - Net topped out at $17.3 million in Q1 2019 and bottomed at $140000.0 in Q3 2022.
  • Average Receivables - Net over 4 years is $5.5 million, with a median of $1.9 million recorded in 2021.
  • The largest annual shift saw Receivables - Net plummeted 96.83% in 2020 before it surged 342.3% in 2021.
  • Summit Therapeutics' Receivables - Net stood at $10.4 million in 2019, then plummeted by 96.83% to $331000.0 in 2020, then soared by 342.3% to $1.5 million in 2021, then crashed by 76.16% to $349000.0 in 2022.
  • Per Business Quant, the three most recent readings for SMMT's Receivables - Net are $349000.0 (Q4 2022), $140000.0 (Q3 2022), and $238000.0 (Q2 2022).